Single-cell sequencing maps the immune battlefield in lupus treatment
A new study published in Arthritis & Rheumatology provides an unprecedented, high-resolution view of how the immune system responds to rituximab therapy in systemic lupus erythematosus (SLE). Using longitudinal single-cell RNA and protein sequencing, researchers tracked over 169,000 immune cells from nine patients before and after B-cell depletion. The analysis revealed that while rituximab effectively depletes naïve, memory, and age-associated B cells, a persistent fraction of antigen-experienced B cells remains, particularly in non-responders. The repopulation phase is dominated by transitional B cells, and responders showed distinct molecular signatures, including reduced NF-κB pathway activation in new B cells and specific gene expression changes in T cell subsets related to cytotoxicity and antigen presentation. This deep molecular profiling offers critical insights into the cellular and clonal dynamics underlying variable patient responses to a common biologic therapy.
Study Significance: For pathologists and molecular diagnosticians, this research underscores the power of single-cell and next-generation sequencing (NGS) to move beyond traditional biomarkers and histopathology for understanding complex autoimmune diseases. It highlights how persistent antigen-experienced B cell clones and specific T cell states may serve as novel predictive biomarkers for treatment response, directly informing more precise diagnostic and prognostic models. This work points toward a future where integrating such detailed molecular diagnostics with classic tissue morphology and immunohistochemistry (IHC) could revolutionize the classification of diseases like lupus and guide personalized therapeutic strategies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
